It meets the birth control pills for weight loss from Eli Lily’s goal in experimenting with the main diabetes

Digest opened free editor

Rola Khaleda, FT editor, chooses her favorite stories in this weekly newsletter.

The American drug group Eli Lilly has announced that the most recent anti -pregnant anti -pregnancy experience has achieved weight loss targets, which enhances its plans to request approval of the drug while fighting to dominate the market with its opponent Novo Nordisk.

Night He said on Tuesday that their birth control pills reduce body weight for people with weight gain and suffer from diabetes by 10.5 percent on average. And note that the side effects were similar to those suffering from injectable weight loss medications.

The results come after I was disappointed the market earlier this month due to the results On average 12.4 percent of body weightAt the bottom of the expectations.

The results will increase its long -term battle for market domination with Novo Nordisk, which in May Present The first birth control pills for weight loss for our organizational approval. Novo pills helped patients with diabetes in the loss of about 9.2 percent of body weight with the highest dose of experiment.

Kenneth Kester, Lily’s CEO, said the company expected that it would provide or manage the US Food and Drug Administration later this year. Analysts said that the FDA can give light next year.

No oral versions of the new generation of popular drugs have been received to treat obesity so far, so the results of the positive experience of night and its competitors are closely monitored.

Birth control pills will also cost to lose weight and store them, as currently injected currents should be cooled.

People with obesity and weight gain with diabetes can find more difficulty in weight loss, depending on their age and other factors. “We are really excited to see () 10.5 percent of weight loss,” Kester said.

But investors Anxiety showed. The results of the previous Lilly experience of Orforglipron have pushed their shares to its lowest level since January 2024. at the end of Monday, its shares decreased 10.6 percent this year, while Novo Nordisk listed in Copenhagen decreased by 43.7 percent during the same period.

After the previous disappointing results, executive officials in Lily and the directors of the Board of Directors bought $ 4.5 million of their shares. This was the more purchase of the interior in the company in one quarter since 2019, according to Veritydata.

On the global level, “more than 1 billion people may benefit from these drugs,” said CUSTER, referring to all obesity drugs. “There is no way we will not be able to get there with the injection.”